Developer docs
API playgroundTry for free, no card

Search company profiles

MediciNova

Full company profile

uuid0002zn8

Namestring
MediciNova
Legal namestring
MediciNova, Inc.
Websiteurl
medicinova.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

MediciNova, Inc. is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in San Diego, California, listed on NASDAQ (MNOV) and the Tokyo Stock Exchange. The company acquires and develops novel, small-molecule therapeutics, with two lead drug candidates: MN-166 (ibudilast), a brain-penetrant small molecule that blocks MIF-CD74 signaling and targets neuroinflammation, currently being evaluated in Phase 2b/3 trials for ALS (COMBAT-ALS) and other neurological indications including progressive multiple sclerosis, glioblastoma (in combination with anti-PD-1 antibodies), and chemotherapy-induced peripheral neuropathy; and MN-001 (tipelukast), a small molecule with anti-inflammatory and anti-fibrotic properties whose metabolite MN-002 enhances cholesterol efflux, in Phase 2 development for hypertriglyceridemia, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes. The company has secured FDA Orphan Drug Designations and Fast Track status for MN-166 in ALS, and holds US patents extending market exclusivity until at least 2040, with a newly allowed glioblastoma combination patent extending to no earlier than September 2042.

MediciNova operates with a lean organization (1-10 employees) and is pre-revenue, with quarterly revenue of approximately $0.15 million and a trailing twelve-month free cash burn of negative $9.73 million. Its revenue model is contingent on future FDA approval and commercialization of its drug candidates, with planned commercialization through direct sales and potential licensing. The company's GTM motion revolves around clinical development through FDA regulatory pathways, participation in investor conferences (e.g., ROTH Conference), and maintaining analyst coverage to attract capital for ongoing Phase 2/3 trials. MediciNova is funded primarily through capital markets activity, including a $30 million Standby Equity Purchase Agreement with Yorkville Advisors and a $50 million at-the-market equity distribution agreement with Lucid Capital Markets, supplemented by a $22 million NIH/NINDS grant for the ALS expanded access program.

The company's customer base, by design, is currently restricted to clinical trial sites and patient populations in the United States, Canada, and Australia, with planned downstream customers being patients, prescribers, and payors upon regulatory approval. The company has received industry recognition including a 2025 BioTech Breakthrough Contract Research and Development Innovation Award for its work on MN-166 in neurological diseases, and has expanded its research collaboration with the Spanish National Cancer Research Centre (CNIO) for biomarker-driven research in brain metastases.

Short descriptiontext

MediciNova is a clinical-stage biopharmaceutical company developing small-molecule drug candidates MN-166 (ibudilast) for neurological and oncological diseases and MN-001 (tipelukast) for metabolic disorders, serving patients with ALS, multiple sclerosis, glioblastoma, and NAFLD through Phase 2/3 clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, biopharmaceutical drug development, neurological disease treatments, metabolic disorder therapies, orphan drug development
Industry3 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing small molecule therapeutics for neurological diseases (ALS, MS), cancer (brain metastasis, glioblastoma), metabolic disorders (hypertriglyceridemia, NAFLD, T2DM), and other conditions. Revenue will be generated upon successful FDA approval and commercialization of drug candidates.

investors.medicinova.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MediciNova is a publicly traded biopharmaceutical company developing novel small-molecule therapeutics for neurological, inflammatory, fibrotic, and metabolic diseases. Its lead drug candidate MN-166 (ibudilast) is a brain-penetrant small molecule in Phase II/III development for ALS, progressive multiple sclerosis, glioblastoma (with anti-PD-1 antibodies), chemotherapy-induced peripheral neuropathy, and brain metastasis. Its second candidate MN-001 (tipelukast) is in Phase 2 for hypertriglyceridemia, NAFLD, and type 2 diabetes.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MediciNova is a biopharmaceutical company developing a portfolio of small-molecule drug candidates for neurological, inflammatory, fibrotic, and metabolic diseases. The company's two lead programs are MN-166 (ibudilast), a brain-penetrant neuroinflammatory inhibitor being advanced through Phase II/III trials for ALS and other neurological conditions, and MN-001 (tipelukast), an anti-inflammatory and anti-fibrotic agent in Phase 2 development for hypertriglyceridemia, NAFLD, and type 2 diabetes. Both candidates have received regulatory designations (Orphan Drug, Fast Track) and patent protection extending into the 2040s.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Collaboration on future biomarker-driven clinical research for patients with solid tumors having brain metastases. Based on peer-reviewed study published in Cancer Research demonstrating MN-166's ability to block MIF-CD74 signaling and suppress brain metastasis growth in preclinical models.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cytokinetics is a late-stage biopharmaceutical company developing small-molecule therapeutics for ALS (reldesemtiv) and other neuromuscular diseases. Directly comparable as a small-molecule CNS/neurology focused public biotech with similar clinical-stage assets.

2AB Science
TypeDirect peer
Description

AB Science is developing masitinib, a small-molecule tyrosine kinase inhibitor, for ALS and other neurological/inflammatory conditions. Directly comparable as a small-molecule clinical-stage company targeting ALS and progressive MS with similar mechanism-of-action challenges.

TypeDirect peer
Description

Clene is developing CNM-Au8, a gold nanocatalyst therapy for ALS, MS, and Parkinson's disease. Comparable as a small clinical-stage biotech pursuing CNS indications with a novel mechanism and similar regulatory pathway considerations.

TypeDirect peer
Description

Annovis Bio is developing buntanetap, a small-molecule for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a small-cap public biotech developing small-molecule therapeutics for CNS indications with similar pre-commercial risk profile.

TypeBroad incumbent
Description

Biogen is a major neurology-focused biopharmaceutical company with approved and pipeline assets in ALS, MS, and rare neurological diseases (Spinraza, Aduhelm, Qalsody). Broad incumbent that competes in MediciNova's target indications with substantially greater resources.

TypeBroad incumbent
Description

Sanofi developed and commercializes tofersen (Qalsody) for SOD1 ALS, directly competing with MediciNova in the ALS therapeutics space. Major global pharmaceutical company with established neurology franchise and commercialization capabilities.

TypeBroad incumbent
Description

Ionis is a leading antisense oligonucleotide platform company developing therapies for neurological diseases including ALS and SMA (with partner Biogen). Broad incumbent in neurology drug development with platform technology spanning multiple CNS indications.

TypeEmerging player
Description

Biohaven develops therapeutics across neurology and rare diseases, including assets for ALS and other CNS conditions. Comparable as a mid-sized neurology-focused biotech pursuing indications overlapping with MediciNova's pipeline.

TypeEmerging player
Description

Cerevel Therapeutics develops small-molecule therapeutics for neuroscience diseases including Parkinson's and epilepsy. Comparable as a CNS-focused clinical-stage company with similar modality (small molecules) and development-stage profile.

TypeBroad incumbent
Description

Denali Therapeutics develops therapeutics for neurodegenerative diseases including ALS, Parkinson's, and Alzheimer's using both small molecules and biologics. Comparable as a well-capitalized neurology biotech with multiple CNS programs in clinical development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MediciNova

Biopharmaceuticalsmedicinova.com

MediciNova is a clinical-stage biopharmaceutical company developing small-molecule drug candidates MN-166 (ibudilast) for neurological and oncological diseases and MN-001 (tipelukast) for metabolic disorders, serving patients with ALS, multiple sclerosis, glioblastoma, and NAFLD through Phase 2/3 clinical trials.

What MediciNova does

MediciNova, Inc. is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in San Diego, California, listed on NASDAQ (MNOV) and the Tokyo Stock Exchange. The company acquires and develops novel, small-molecule therapeutics, with two lead drug candidates: MN-166 (ibudilast), a brain-penetrant small molecule that blocks MIF-CD74 signaling and targets neuroinflammation, currently being evaluated in Phase 2b/3 trials for ALS (COMBAT-ALS) and other neurological indications including progressive multiple sclerosis, glioblastoma (in combination with anti-PD-1 antibodies), and chemotherapy-induced peripheral neuropathy; and MN-001 (tipelukast), a small molecule with anti-inflammatory and anti-fibrotic properties whose metabolite MN-002 enhances cholesterol efflux, in Phase 2 development for hypertriglyceridemia, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes. The company has secured FDA Orphan Drug Designations and Fast Track status for MN-166 in ALS, and holds US patents extending market exclusivity until at least 2040, with a newly allowed glioblastoma combination patent extending to no earlier than September 2042.

MediciNova operates with a lean organization (1-10 employees) and is pre-revenue, with quarterly revenue of approximately $0.15 million and a trailing twelve-month free cash burn of negative $9.73 million. Its revenue model is contingent on future FDA approval and commercialization of its drug candidates, with planned commercialization through direct sales and potential licensing. The company's GTM motion revolves around clinical development through FDA regulatory pathways, participation in investor conferences (e.g., ROTH Conference), and maintaining analyst coverage to attract capital for ongoing Phase 2/3 trials. MediciNova is funded primarily through capital markets activity, including a $30 million Standby Equity Purchase Agreement with Yorkville Advisors and a $50 million at-the-market equity distribution agreement with Lucid Capital Markets, supplemented by a $22 million NIH/NINDS grant for the ALS expanded access program.

The company's customer base, by design, is currently restricted to clinical trial sites and patient populations in the United States, Canada, and Australia, with planned downstream customers being patients, prescribers, and payors upon regulatory approval. The company has received industry recognition including a 2025 BioTech Breakthrough Contract Research and Development Innovation Award for its work on MN-166 in neurological diseases, and has expanded its research collaboration with the Spanish National Cancer Research Centre (CNIO) for biomarker-driven research in brain metastases.

MediciNova firmographics

Firmographics
Name
MediciNova
Legal name
MediciNova, Inc.
Website
https://medicinova.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule drug candidates MN-166 (ibudilast) for neurological and oncological diseases and MN-001 (tipelukast) for metabolic disorders, serving patients with ALS, multiple sclerosis, glioblastoma, and NAFLD through Phase 2/3 clinical trials.
Ownership category
akta.pro rank

MediciNova industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Biopharmaceutical drug development
  • Neurological disease treatments
  • Metabolic disorder therapies
  • Orphan drug development

Where MediciNova is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MediciNova business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing small molecule therapeutics for neurological diseases (ALS, MS), cancer (brain metastasis, glioblastoma), metabolic disorders (hypertriglyceridemia, NAFLD, T2DM), and other conditions. Revenue will be generated upon successful FDA approval and commercialization of drug candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

MediciNova product offering

Product offering

Core offering

MediciNova is a publicly traded biopharmaceutical company developing novel small-molecule therapeutics for neurological, inflammatory, fibrotic, and metabolic diseases. Its lead drug candidate MN-166 (ibudilast) is a brain-penetrant small molecule in Phase II/III development for ALS, progressive multiple sclerosis, glioblastoma (with anti-PD-1 antibodies), chemotherapy-induced peripheral neuropathy, and brain metastasis. Its second candidate MN-001 (tipelukast) is in Phase 2 for hypertriglyceridemia, NAFLD, and type 2 diabetes.

Product overview

MediciNova is a biopharmaceutical company developing a portfolio of small-molecule drug candidates for neurological, inflammatory, fibrotic, and metabolic diseases. The company's two lead programs are MN-166 (ibudilast), a brain-penetrant neuroinflammatory inhibitor being advanced through Phase II/III trials for ALS and other neurological conditions, and MN-001 (tipelukast), an anti-inflammatory and anti-fibrotic agent in Phase 2 development for hypertriglyceridemia, NAFLD, and type 2 diabetes. Both candidates have received regulatory designations (Orphan Drug, Fast Track) and patent protection extending into the 2040s.

Differentiator

Problem solved

Functional benefit

Companies that use MediciNova

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles1 record

MediciNova technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

MediciNova partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CNIO (Spanish National Cancer Research Centre)minorStrategic or Co-development Partner · 27 April 2026Collaboration on future biomarker-driven clinical research for patients with solid tumors having brain metastases. Based on peer-reviewed study published in Cancer Research demonstrating MN-166's ability to block MIF-CD74 signaling and suppress brain metastasis growth in preclinical models.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

MediciNova competitors and assessment

Company assessment

Direct peers

  • Cytokinetics: Cytokinetics is a late-stage biopharmaceutical company developing small-molecule therapeutics for ALS (reldesemtiv) and other neuromuscular diseases. Directly comparable as a small-molecule CNS/neurology focused public biotech with similar clinical-stage assets.
  • AB Science: AB Science is developing masitinib, a small-molecule tyrosine kinase inhibitor, for ALS and other neurological/inflammatory conditions. Directly comparable as a small-molecule clinical-stage company targeting ALS and progressive MS with similar mechanism-of-action challenges.
  • Clene Nanomedicine: Clene is developing CNM-Au8, a gold nanocatalyst therapy for ALS, MS, and Parkinson's disease. Comparable as a small clinical-stage biotech pursuing CNS indications with a novel mechanism and similar regulatory pathway considerations.
  • Annovis Bio: Annovis Bio is developing buntanetap, a small-molecule for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a small-cap public biotech developing small-molecule therapeutics for CNS indications with similar pre-commercial risk profile.

Broad incumbents

  • Biogen: Biogen is a major neurology-focused biopharmaceutical company with approved and pipeline assets in ALS, MS, and rare neurological diseases (Spinraza, Aduhelm, Qalsody). Broad incumbent that competes in MediciNova's target indications with substantially greater resources.
  • Sanofi: Sanofi developed and commercializes tofersen (Qalsody) for SOD1 ALS, directly competing with MediciNova in the ALS therapeutics space. Major global pharmaceutical company with established neurology franchise and commercialization capabilities.
  • Ionis Pharmaceuticals: Ionis is a leading antisense oligonucleotide platform company developing therapies for neurological diseases including ALS and SMA (with partner Biogen). Broad incumbent in neurology drug development with platform technology spanning multiple CNS indications.
  • Denali Therapeutics: Denali Therapeutics develops therapeutics for neurodegenerative diseases including ALS, Parkinson's, and Alzheimer's using both small molecules and biologics. Comparable as a well-capitalized neurology biotech with multiple CNS programs in clinical development.

Emerging players

  • Biohaven Pharmaceuticals: Biohaven develops therapeutics across neurology and rare diseases, including assets for ALS and other CNS conditions. Comparable as a mid-sized neurology-focused biotech pursuing indications overlapping with MediciNova's pipeline.
  • Cerevel Therapeutics: Cerevel Therapeutics develops small-molecule therapeutics for neuroscience diseases including Parkinson's and epilepsy. Comparable as a CNS-focused clinical-stage company with similar modality (small molecules) and development-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

MediciNova social profiles

Digital presence

MediciNova financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MediciNova leadership team

Management profile

Number of profiles

Profiles9 records

MediciNova funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MediciNova M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediciNova

What does MediciNova do?

MediciNova is a publicly traded biopharmaceutical company developing novel small-molecule therapeutics for neurological, inflammatory, fibrotic, and metabolic diseases. Its lead drug candidate MN-166 (ibudilast) is a brain-penetrant small molecule in Phase II/III development for ALS, progressive multiple sclerosis, glioblastoma (with anti-PD-1 antibodies), chemotherapy-induced peripheral neuropathy, and brain metastasis. Its second candidate MN-001 (tipelukast) is in Phase 2 for hypertriglyceridemia, NAFLD, and type 2 diabetes.

Is MediciNova a public or private company?

MediciNova is a public company. It is classified as public and is currently operating.

When was MediciNova founded?

MediciNova was founded in 2000. It employs 11 to 50 people.

Where is MediciNova based?

MediciNova is headquartered in San Diego, United States, in the North America region.

How does MediciNova make money?

One revenue line is on record: drug Development and Commercialization.

Who are MediciNova's main competitors?

Direct peers on record are Cytokinetics, AB Science, Clene Nanomedicine and Annovis Bio. Broad incumbents are Biogen, Sanofi, Ionis Pharmaceuticals and Denali Therapeutics. Emerging players are Biohaven Pharmaceuticals and Cerevel Therapeutics.

Does MediciNova have an API?

No public API is recorded for MediciNova.

What industry is MediciNova in?

MediciNova's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingMediciNova Inc reports results for the quarter ended September 30 - Earnings SummaryMediciNova Inc reported a quarterly adjusted loss of 6 cents per share for the quarter ended September 30, matching the prior year. Revenue rose 12.7% to $139.00 thousand, beating analyst expectations of $50.00 thousand. The company's shares fell 16.4% this quarter but gained 6.9% year-to-date.American Banking and Market NewsMediciNova, Inc. (NASDAQ:MNOV) Stock Rated “Moderate Buy” by Sell-Side AnalystsMediciNova's stock received an average "Moderate Buy" rating from seven analysts, with a $7.75 target price. Major shareholder 3D Investment Partners sold 640,000 shares at $2.70, while Bank of New York Mellon bought a new position. The company reported Q2 EPS of -$0.05, beating estimates, with revenue of $0.46 million.American Banking and Market NewsMediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of “Moderate Buy” from AnalystsMediciNova's shares received a consensus "Moderate Buy" rating from seven analysts, with an average price target of $7.75. Major shareholder 3D Investment Partners sold 640,000 shares at $2.70, while Bank of New York Mellon bought a new stake. The company reported a loss of $0.05 EPS for the quarter, beating estimates.MarketBeatMediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from AnalystsMediciNova shares received a consensus 'Moderate Buy' rating from seven analysts, with an average 12-month price target of $7.75. Major shareholder 3D Investment Partners sold 640,000 shares at $2.70, reducing its stake by 11.63%, while Bank of New York Mellon acquired a new position. The company reported a loss of $0.05 EPS for the quarter, beating estimates.American Banking and Market NewsMerck KGaA (OTCMKTS:MKKGY) vs. MediciNova (NASDAQ:MNOV) Head-To-Head ContrastMerck KGaA and MediciNova are compared across profitability, valuation, and analyst ratings. Merck KGaA beats MediciNova on 8 of 15 factors, with higher revenue and earnings, but MediciNova has a lower P/E ratio and a higher consensus price target of $7.75.AInvestMediciNova (MNOV) fell 19.42% intraday after gaining 36.9% on Thursday.MediciNova (MNOV) fell 19.42% in intraday trading on Friday after rising 36.9% on Thursday, marking a reversal of the prior session's move. The stock's intraday decline followed the earlier gain, with no further details provided.Ticker ReportMediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Roth CapitalRoth Capital upgraded MediciNova to a strong-buy rating, while Weiss Ratings downgraded it to sell (d-). The company reported Q2 EPS of -$0.05, beating estimates, and revenue of $0.46 million. Bank of New York Mellon acquired a new stake of 78,277 shares.Investing.comMediciNova earnings beat by $0.02, revenue topped estimates By Investing.comMediciNova reported second-quarter earnings of -$0.060 per share, beating analyst estimates of -$0.077 by $0.02. The company's revenue for the quarter reached $75,000, surpassing the consensus estimate of $65,000.Clinical Trials ArenaMediciNova achieves target enrolment in SEANOBI-ALS study of MN-166MediciNova achieved target enrolment of 200 patients in the SEANOBI-ALS study evaluating MN-166 (ibudilast) for ALS. The NIH-funded study provides expanded access for patients not eligible for ongoing trials, with final follow-ups expected in early 2027. The company plans a data analysis phase led by an academic investigator.Quiver QuantitativeMediciNova Achieves Full Enrollment in NIH-Funded SEANOBI-ALS Study of MN-166 (Ibudilast) for ALS | Quiver QuantitativeMediciNova announced the achievement of full enrollment with 200 patients in the SEANOBI-ALS study, an NIH-funded Expanded Access Program evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) treatment. The milestone reflects strong engagement from the ALS community, with final patient follow-ups projected to conclude in early 2027, triggering the data analysis phase for scientific presentations and peer-reviewed publications. MN-166 (ibudilast) has received Orphan Drug Designation from both the U.S. FDA and EU EMA, as well as Fast Track Designation from the FDA for ALS.